Respiratory Medicine and Research最新文献

{"title":"Burden of unexplained dyspnea: a single-center study","authors":"Anissa Reguig ,&nbsp;Clémence Remy ,&nbsp;Lidwine Wemeau ,&nbsp;David Montaigne ,&nbsp;Thierry Perez ,&nbsp;Cécile Chenivesse ,&nbsp;Nathalie Bautin","doi":"10.1016/j.resmer.2025.101234","DOIUrl":"10.1016/j.resmer.2025.101234","url":null,"abstract":"<div><div>Unexplained dyspnea refers to unpleasant breathing sensations without any disorder being diagnosed. We aimed to study the burden of unexplained dyspnea, by assessing health-related quality of life (SF-36 questionnaire), characteristics of dyspnea (mMRC, multidimensional dyspnea profile (MDP) and Borg score at exercise), hyperventilation symptoms (Nijmegen questionnaire), anxiety and depression (HAD scale), exercise capacity (peak V̇O2) and ventilatory response to exercise. Of the 62 patients referred to our Dyspnea center, we included 29 patients with confirmed unexplained dyspnea after a complete systematic evaluation (a cause of dyspnea was found in 29 patients and 4 cases were excluded for missing values)<em>.</em> They were aged 57 years [47;66], including 20 (69 %) women. All SF-36 scores were low: physical functioning 50 [33;75], limitation due to physical health 50 [0;63], limitation due to emotional problems 67 [0;100], fatigue 30 [15;43], emotional well-being 52 [44;66], social functioning 63 [38;75], bodily pain 45 [23;58], general health 50 [30;55]. Most patients (23 (79 %)) had activity-limiting dyspnea (mMRC≥2), 15 (55 %) had a low exercise capacity (peakV’O2&lt;85 %) and 20 (74 %) had either exertional hyperventilation (threshold V̇E/V̇CO2&gt;34) or low Vt expansion (peak Vt/FVC&lt;40 %). Hyperventilation symptoms (Nijmegen&gt;23) were present in 17 (59 %) patients, and associated with lower scores in some domains of the SF-36 questionnaire and higher HAD and MDP anxiety subscores. Our results suggest a heavy burden of unexplained dyspnea on physical and mental health. Expert centers may help in the diagnosis and thus enable earlier symptomatic management.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101234"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apical and basolateral alpha-1 antitrypsin delivery modulate CFTR and STAT3 in human airway epithelia grown at air-liquid interface","authors":"Kokilavani Sivaraman ,&nbsp;Stephanie Tamm ,&nbsp;Elena Korenbaum ,&nbsp;Beata Olejnicka ,&nbsp;Wenzhang Si ,&nbsp;Sabine Wrenger ,&nbsp;Frauke Stanke ,&nbsp;Sabina Janciauskiene","doi":"10.1016/j.resmer.2025.101236","DOIUrl":"10.1016/j.resmer.2025.101236","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101236"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An original story of a coma","authors":"Malo Miquel ,&nbsp;Cécile Devloo ,&nbsp;Alexandre Vasseur ,&nbsp;Jéromine Alessandri ,&nbsp;Jean-Philippe Rigaud ,&nbsp;Pierre-Louis Declercq","doi":"10.1016/j.resmer.2025.101241","DOIUrl":"10.1016/j.resmer.2025.101241","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101241"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse infiltrative lymphocytic syndrome in recently diagnosed HIV patient: a case-report DILS-ILD responsive to steroids","authors":"Nicolas Duhamel ,&nbsp;Pierre-Yves Jeandel ,&nbsp;Marie Ottavi ,&nbsp;Giorgio Toni ,&nbsp;Julie Merindol ,&nbsp;Michael Levraut","doi":"10.1016/j.resmer.2025.101223","DOIUrl":"10.1016/j.resmer.2025.101223","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101223"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145521165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France","authors":"Maurice Pérol ,&nbsp;Clarisse Audigier-Valette ,&nbsp;Hervé Léna ,&nbsp;Marie-Ange Massiani ,&nbsp;Xavier Quantin ,&nbsp;Melissa Santorelli ,&nbsp;Marion Apert ,&nbsp;Axelle Spampinato ,&nbsp;Thomas Burke ,&nbsp;Christos Chouaid","doi":"10.1016/j.resmer.2025.101238","DOIUrl":"10.1016/j.resmer.2025.101238","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101238"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145866034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vibrating mesh nebulization increases tidal volume relative to jet nebulization during NIV in COPD exacerbation","authors":"César Cinesi-Gomez,&nbsp;María Garcia-Palacios,&nbsp;Lorena Bernabe-Vera,&nbsp;Mabel Coromoto Suarez-Pineda,&nbsp;Elisa Serrano-Carrasco,&nbsp;Jose Andres Sanchez-Nicolas","doi":"10.1016/j.resmer.2026.101248","DOIUrl":"10.1016/j.resmer.2026.101248","url":null,"abstract":"<div><h3>Background and importance</h3><div>Noninvasive ventilation (NIV) is the first-line treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD) with hypercapnic respiratory failure (HRF). Bronchodilator therapy is essential during NIV, but real-world clinical comparisons of nebulization devices in this acute setting remain limited.</div></div><div><h3>Objective</h3><div>To compare the clinical efficacy of vibrating mesh nebulizers (VMN) versus jet nebulizers (JN) in COPD patients undergoing NIV, using changes in tidal volume (VT) as the primary outcome.</div></div><div><h3>Design, settings and participants</h3><div>A longitudinal observational study was performed in the ventilatory unit of the emergency department of a tertiary hospital. Patients requiring NIV for HRF were allocated to two cohorts: VMN (October 2023–March 2024) and JN (January 2015–May 2017). Ventilatory parameters, including VT, were recorded at baseline, 15 minutes, 1 hour, and 3 hours. The primary outcome was the percentage change in VT (ΔVT) from baseline.</div></div><div><h3>Main results</h3><div>Eighty-four patients were analyzed (VMN: n=41; JN: n=43). Baseline characteristics were comparable between groups. The VMN cohort exhibited a significantly greater increase in VT at 1 hour and 3 hours (p&lt;0.05) compared with the JN cohort. ΔVT mirrored these findings. No significant correlation was observed between VT and pressure support levels.</div></div><div><h3>Conclusion</h3><div>In this real-world ED study of COPD patients treated with continuous NIV, VMN was associated with a greater early increase in VT than JN, consistent with more effective bronchodilator delivery. Given the historical, non-randomized design across different time periods and ventilators, and the use of VT as an indirect endpoint, these findings should be interpreted as hypothesis-generating but provide a clinically relevant starting point supporting preferential VMN use in acute practice.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101248"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a pulmonary rehabilitation maintenance program on long-term healthcare resource utilization and costs in COPD patients: ancillary analysis from a real-life post-rehabilitation cohort","authors":"Fares Gouzi ,&nbsp;Thomas Espie ,&nbsp;Steven Lopes ,&nbsp;Hélène Forthin ,&nbsp;Elise Galmes ,&nbsp;Léo Blervaque ,&nbsp;Christian Préfaut ,&nbsp;François Carbonnel","doi":"10.1016/j.resmer.2025.101243","DOIUrl":"10.1016/j.resmer.2025.101243","url":null,"abstract":"<div><h3>Rational</h3><div>Chronic Obstructive Pulmonary Disease (COPD) is a major cause of healthcare system use and related cost. While pulmonary rehabilitation (PR) is efficient, maintenance programs (PR-MA) can maintain the benefits over time. Yet, the long-term impact (&gt;36 months) of PR-MA on healthcare resource and cost has never been assessed. Recently, a PR-MA program based on self-help associations has shown a clinical efficacy beyond 36 months, Thus, we aimed to assess the effect of this PR-MA program on long-term hospitalizations and costs versus usual care (PR-UC).</div></div><div><h3>Methods</h3><div>We performed an ancillary analysis of the post-rehabilitation LTAir+R cohort study, which compared a PR-MA group (n=144) to a matched PR-UC group (n=137) of COPD patients. Data were collected in 82 PR-MA and 93 PR-UC patients, from the Montpellier University Hospital database and patient records over 60 months, including hospitalizations, consultations, emergency visits, and associated costs.</div></div><div><h3>Results</h3><div>In PR-AM vs. PR-UC group, the hospitalization probability reduction almost reached significance (hazard ratio: 1.68; p=0.05). The costs of each hospitalization day (867±116 vs. 1213±138 euros/day; p&lt;0.05), emergency visits (8±5 euros/year vs. 12±3 euros/year) and medical consultations (110±3 vs. 174±3 euros/year; p&lt;0.01) were significantly lower in the PR-AM vs. PR-UC group. Last, PR-MA mitigated the increase in total hospitalizations (p&lt;0.001) associated with the follow-up duration.</div></div><div><h3>Conclusion</h3><div>In addition to its long-term clinical efficacy, this PR-MA program showed a positive impact on hospitalization and healthcare use costs. The effect on hospitalization number and costs could be larger in patients with the longest PR-MA adherence.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101243"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peridiaphragmatic inflammation and fibrosis in myositis associated interstitial lung disease; a case series","authors":"Joseph B. Pryor ,&nbsp;Joshua J. Solomon ,&nbsp;Jeffrey J. Swigris ,&nbsp;Tami J. Bang ,&nbsp;Andrea Fuentealba ,&nbsp;Rebecca Keith ,&nbsp;Michael P. Mohning ,&nbsp;Matthew Koslow ,&nbsp;Evans R. Fernández Pérez ,&nbsp;Tristan J. Huie ,&nbsp;Joseph Cooley ,&nbsp;Cori Fratelli ,&nbsp;David A. Lynch ,&nbsp;Zulma X. Yunt ,&nbsp;Liudmila Kastsianok","doi":"10.1016/j.resmer.2025.101219","DOIUrl":"10.1016/j.resmer.2025.101219","url":null,"abstract":"<div><h3>Introduction</h3><div>Peridiaphragmatic inflammation and fibrosis (PDIF) is a radiologic feature in myositis-associated interstitial lung disease (M-ILD). This study aims to formally define PDIF as seen on high-resolution computed tomography (HRCT) and evaluate its association with clinical and serologic features of M-ILD.</div></div><div><h3>Methods</h3><div>We conducted a retrospective review of 46 patients diagnosed with M-ILD at National Jewish Health, who were evaluated for the presence of PDIF on HRCT scans. Three thoracic radiologists developed the criteria, and two independently assessed 169 longitudinal CT scans from the 46 patients for predefined imaging criteria, including PDIF. Demographic, clinical, serologic, and pulmonary function test data were collected and analyzed.</div></div><div><h3>Results</h3><div>PDIF was identified in 28.2 % (13/46) of patients and in 18.9 % (32/169) of the reviewed scans. Among those with PDIF, 69.2 % had this finding on their initial HRCT scan prior to starting therapy, and it persisted in subsequent scans. PDIF was associated with stable radiologic pattern over time. Patients with PDIF had a high prevalence of anti-Jo antibodies (69 %) and anti-Ro52 antibodies (61.5 %). Despite ongoing treatment, all patients with PDIF experienced dyspnea, and 8/13 had concurrent myositis. There was no significant difference in forced vital capacity (FVC) or diffusing capacity for carbon monoxide (DLCO) trends over time between patients with and without PDIF.</div></div><div><h3>Conclusion</h3><div>PDIF is a relatively common finding in M-ILD, and appears to be particularly associated with anti-synthetase syndrome. Further research is needed to determine the sensitivity, specificity, and clinical implications of PDIF across all inflammatory ILDs. Early recognition of PDIF may aid in the diagnosis and management of M-ILD, but does not appear to be associated with disease progression.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101219"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145597947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased delays of care during the COVID-19 pandemic: experience of a lung cancer rapid diagnostic center","authors":"Pascal Wang ,&nbsp;Anthony Canellas ,&nbsp;Floriane Millet ,&nbsp;Constance Météyé ,&nbsp;Christelle Epaud ,&nbsp;Lise Rosencher ,&nbsp;Martine Antoine ,&nbsp;Harry Etienne ,&nbsp;Matthias Barral ,&nbsp;Jacques Cadranel ,&nbsp;Antoine Parrot ,&nbsp;Vincent Fallet ,&nbsp;et Armelle Lavolé","doi":"10.1016/j.resmer.2025.101237","DOIUrl":"10.1016/j.resmer.2025.101237","url":null,"abstract":"<div><h3>Context</h3><div>The COVID-19 pandemic has disrupted hospital organisation and management of chronic pathologies, such as lung cancer. Our objective was to evaluate the impact of COVID-19 on delays in lung cancer care at a French Lung Cancer Rapid Diagnostic Center (RDC).</div></div><div><h3>Methods</h3><div>All patients diagnosed with lung cancer through the RDC at Tenon hospital were included in this retrospective study. The main outcomes were delays (in days) of medical (diagnosis and treatment) care over two periods: period 1 in 2016 (P1, pre-COVID) and period 2 in 2020 (P2, during COVID). Two individualized pathways were considered based on the type of first treatment (surgery or chemo ± immunotherapy).</div></div><div><h3>Results</h3><div>A total of 227 and 293 patients were referred to the RDC during periods P1 and P2, respectively. Lung cancer was diagnosed in 118 patients (52 %) in P1 and 145 patients (49.5 %) in P2 (p=0.29). Patient characteristics were comparable between the two periods, except for TNM stage. A higher proportion of patients with localised stage was diagnosed in P2 compared to P1 (42.1 %¦vs 29.7 %; p=0.02). All delays increased significantly during P2, both pre-hospital steps (e.g. the delay in accessing the first consultation at RDC, which increased from 4 to 13 days, p &lt; 0.0001) and in-hospital steps (e.g. the delay from the first consultation at RDC to the first treatment, which rose from 37.5 to 49 days, p &lt; 0.0001). The surgery pathway was the most impacted, with a significant increase in the overall delay (67 days in P1 vs 109 days in P2, p &lt; 0.0001). The only delay that did not increase between P1 and P2 was the delay in accessing molecular biology.</div></div><div><h3>Conclusions</h3><div>Although the RDC remained open, our delays in lung cancer care increased during the COVID-19 pandemic. These increased delays particularly affected the management of localised lung cancers, which are the most curable. Given the shift toward ambulatory care outlined in the new 2021-2030 National Cancer Plan established by french health authorities, regular evaluations of care delays should be conducted, particularly in the context of health crisis.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101237"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic liposomal amphotericin B therapy in semi-invasive pulmonary aspergillosis","authors":"Benoit Aguado ,&nbsp;Julia Ballouhey ,&nbsp;Yannick Simonneau ,&nbsp;Thomas Egenod ,&nbsp;Stéphane Moreau ,&nbsp;Elsa Clapaud","doi":"10.1016/j.resmer.2025.101233","DOIUrl":"10.1016/j.resmer.2025.101233","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101233"},"PeriodicalIF":1.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}